NeuroSense Targets Canadian Regulatory Filing for ALS Therapy

NeuroSense is currently navigating the regulatory landscape for PrimeC, an investigational oral combination therapy designed to address the progression of amyotrophic lateral sclerosis. Following a constructive Pre-New Drug Submission process, the company has secured alignment with Health Canada regarding the structure and content of its upcoming filing. CEO Alon Ben-Noon emphasized that the firm is prioritizing capital-efficient development, aiming to advance the program through strategic partnerships and potential non-dilutive funding sources.

The company’s late-stage clinical confidence rests on the PARADIGM Phase 2b study, which recently achieved its primary endpoint by demonstrating a significant reduction in extracellular vesicle-associated TDP-43. Peer-reviewed results published in JAMA Neurology further bolstered the case for PrimeC, reporting an estimated median survival of 36.3 months for continuous treatment participants, compared to 21.4 months for those initially on a placebo. As development continues, NeuroSense is evaluating a smaller, streamlined pivotal design for the U.S. and remains in active discussions with the FDA regarding potential pathways to full or accelerated approval.